遗传与T2生物标志物关联屋尘螨舌下免疫治疗哮喘疗效
MITRA试验事后分析纳入742例屋尘螨过敏性哮喘成人,评估T2炎症与遗传生物标志物与疾病严重度的关联及舌下免疫治疗的修饰作用。SNP rs7216389纯合子患者经治疗哮喘急性发作风险降低(HR=0.37,95%CI 0.22-0.64,p<0.001),高T2生物标志物水平者在安慰剂组发作风险增加,治疗可降低该风险。
要点
- SNP rs7216389纯合子患者接受屋尘螨舌下免疫治疗后急性发作风险显著降低。
- 高T2生物标志物水平与安慰剂组哮喘急性发作风险增加相关,治疗可降低此风险。
- T2生物标志物升高数量越多,舌下免疫治疗效应越强(p=0.006)。
核心结论
- 屋尘螨舌下免疫治疗对具有遗传哮喘易感性和/或T2内型的屋尘螨致敏哮喘患者有效。
研究设计与样本
- MITRA(NCT01433523)为III期随机双盲安慰剂对照试验,事后分析纳入742例屋尘螨过敏性哮喘成人。
- T2炎症生物标志物包括血嗜酸性粒细胞、嗜酸性粒细胞阳离子蛋白(ECP)、总IgE和类胰蛋白酶。
- 遗传生物标志物为单核苷酸多态性(SNP),共分析582例。
- SNP关联在独立3年严重哮喘研究计划(SARP3)屋尘螨阳性亚组中验证。
主要发现
- SNP rs7216389(染色体位点17q12-21)纯合子患者哮喘急性发作风险增加,经屋尘螨舌下免疫治疗降低(p=0.037),HR=0.37(95%CI 0.22-0.64),p<0.001。
- 17q12-21区域SNP与急性发作风险的关联在SARP3屋尘螨阳性亚组中重复验证。
- 安慰剂组中高T2生物标志物水平与哮喘急性发作风险增加相关。
- 屋尘螨舌下免疫治疗降低高T2生物标志物者的发作风险:血嗜酸性粒细胞HR=0.50(95%CI 0.30-0.85);ECP HR=0.45(95%CI 0.29-0.87);类胰蛋白酶HR=0.45(95%CI 0.25-0.80)。
- T2生物标志物升高数量较多的受试者治疗效应更高(p=0.006)。
临床怎么用
- 对屋尘螨致敏的过敏性哮喘患者,可考虑检测SNP rs7216389及T2生物标志物以识别可能从舌下免疫治疗获益的人群。
局限性
- 本研究为事后分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypersensitivity to house dust mite (HDM) allergens is a common cause of allergic asthma symptoms and can be effectively treated with allergy immunotherapy (AIT). OBJECTIVE: To investigate whether genetic and type 2 (T2) inflammatory biomarkers correlate with disease severity in subjects with allergic asthma, and whether this can be modified by AIT. METHODS: MITRA (NCT01433523) was a phase III, randomised, double-blind, placebo-controlled trial of HDM sublingual immunotherapy (SLIT)-tablets in adults with HDM allergic asthma. Post hoc analyses of the study population (N=742) evaluated associations between T2 inflammatory (blood eosinophils, eosinophil cationic protein (ECP), total IgE and tryptase) and genetic (single-nucleotide polymorphisms, SNP) biomarkers (n=582) for the primary study endpoint (time to first moderate/severe asthma exacerbation). SNP associations were verified in HDM-positive subgroup from an independent 3-year Severe Asthma Research Programme (SARP3) subject cohort. RESULTS: An increased asthma exacerbation risk in subjects homozygous for SNP rs7216389 (chromosomal locus 17q12-21) was reduced (p=0.037) by treatment with HDM SLIT (HR=0.37 (95% CI 0.22 to 0.64), p<0.001). The associations between exacerbation risk and 17q12-21 SNPs were replicated in the SARP3 HDM-positive subgroup. High levels of T2 biomarkers were associated with increased risk of asthma exacerbations in the placebo group. HDM SLIT-tablet treatment reduced this risk (blood eosinophils: HR=0.50 (95% CI 0.30 to 0.85); ECP: HR=0.45 (95% CI 0.29 to 0.87); tryptase: HR=0.45 (95% CI 0.25 to 0.80)). The treatment effect was higher (p=0.006) for subjects with a higher number of elevated T2 biomarkers. CONCLUSIONS: HDM SLIT-tablet AIT is efficacious in HDM-sensitised asthma subjects with a genetic asthma predisposition and/or an underlying T2 endotype. TRIAL REGISTRATION NUMBER: NCT01433523.
引用
- Hoof, Bønnelykke, Stranzl, et al. Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma. Thorax. 2024. PMID: 38160049. doi:10.1136/thorax-2023-220707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。